Business Description
Fennec Pharmaceuticals is a North Carolina-based company focused on protecting children undergoing cancer treatment from hearing loss caused by the chemotherapy drug cisplatin. Its approved product, PEDMARK, is the only therapy specifically designed to address this side effect in pediatric patients. The company works with pediatric cancer specialists across the United States to deliver this treatment and is also studying whether it may benefit older adolescents and adults through a partnership with Tampa General Hospital. Fennec has operated under its current name since 2014, having originally been founded in 1996.
